STXS Stereotaxis

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025

ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.

What:Stereotaxis third quarter 2025 financial results conference call
When:Tuesday, November 11, 2025, at 4:30 p.m. ET (1:30 p.m. PT)
Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 4402192.
Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at .
Call Replay:A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please .



About Stereotaxis


(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit .

Investor Contacts:                                        

David L. Fischel                                        

Chairman and Chief Executive Officer                        

                                                        

Kimberly Peery                                                

Chief Financial Officer

314-678-6100



EN
21/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE

Stereotaxis Reports 2025 Third Quarter Financial Results

Stereotaxis Reports 2025 Third Quarter Financial Results ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” said David Fischel, Chairman and CEO. “This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial...

 PRESS RELEASE

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearanc...

GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its latest generation robotic system, . GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the technology for healthcare providers. The sys...

 PRESS RELEASE

Stereotaxis to Report Third Quarter 2025 Financial Results on November...

Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025 ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis third quarter 2025 financial results conferen...

 PRESS RELEASE

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony Sy...

Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the US for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony’s slim and stunning 55” 4K ultra-high-definition display consolidates the viewing and control o...

 PRESS RELEASE

Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field ...

Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced they have entered into a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology towards commercialization. The collaboration combines the pr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch